Episode 194 ESMO 2022: Pegylated il-2 + nivolumab in renal cancer

The Uromigos - A podcast by The Uromigos

Podcast artwork

Nizar Tannir describes this randomised phase 3 study presented at ESMO.

Visit the podcast's native language site